1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma.

Archive ouverte

Fournier, Alexandra | Mcleer-Florin, Anne | Lefebvre, Christine | Duley, Samuel | Barki, Leila | Ribeyron, Juliana | Alboukadel, Kassambara | Hamaidia, Sieme | Granjon, Aurélie | Gressin, Rémy | Lajmanovich, Alicia | Bonnefoix, Thierry | Chauvelier, Stéphanie | Debernardi, Alexandra | Rousseaux, Sophie | de Fraipont, Florence | Figeac, Martin | Kerckaert, Jean-Pierre | de Vos, John | Usson, Yves | Delaval, Katia | Grichine, Alexei | Vourc'H, Claire | Khochbin, Saadi | Feil, Robert | Leroux, Dominique | Callanan, Mary, B.

Edité par CCSD ; Wiley Open Access -

International audience. Epigenetic perturbations are increasingly described in cancer cells where they are thought to contribute to deregulated gene expression and genome instability. Here, we report the first evidence that a distinct category of chromosomal translocations observed in human tumours--those targeting 1q12 satellite DNA--can directly mediate such perturbations by promoting the formation of aberrant heterochromatic foci (aHCF). By detailed investigations of a 1q12 translocation to chromosome 2p, in a case of human B cell lymphoma, aberrant aHCF were shown to be localized to the nuclear periphery and to arise as a consequence of long range 'pairing' between the translocated 1q12 and chromosome 2 centromeric regions. Remarkably, adjacent 2p sequences showed increased levels of repressive histone modifications, including H4K20me3 and H3K9me3, and were bound by HP1. aHCF were associated to aberrant spatial localization and deregulated expression of a novel 2p gene (GMCL1) that was found to have prognostic impact in diffuse large B cell lymphoma. Thus constitutive heterochromatin rearrangements can contribute to tumourigenesis by perturbing gene expression via long range epigenetic mechanisms.

Suggestions

Du même auteur

Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance

Archive ouverte | Emadali, Anouk | CCSD

International audience. Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refracto...

Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma.

Archive ouverte | Lajmanovich, Alicia | CCSD

International audience. CD95 gene and splicing aberrations have been detected in B-cell non-Hodgkin lymphoma (B-NHL) where they are thought to contribute to CD95 apoptosis resistance. To further investigate this, we...

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL

Archive ouverte | Bouroumeau, Antonin | CCSD

International audience. R-CHOP immuno-chemotherapy significantly improved clinical management of diffuse large B-cell lymphoma (DLBCL). However, 30\textendash 40% of DLBCL patients still present a refractory disease...

Chargement des enrichissements...